Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ana Beatriz M. L. A. Tavares"'
Publikováno v:
Physical Chemistry Chemical Physics. 23:21207-21217
We investigate the interaction between the programmed cell death protein 1 (PD-1) and the programmed cell death ligand 1 (PD-L1), as well as the immuno-oncological drugs pembrolizumab (PEM), and nivolumab (NIV), through quantum chemistry methods base
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b3c4c7840c25703108e2686b9d48160
https://doi.org/10.1039/d1cp03064g
https://doi.org/10.1039/d1cp03064g
Publikováno v:
New Journal of Chemistry. 43:7185-7189
Targeted immunotherapy has reignited enthusiasm for the development of checkpoint inhibitor drugs for cancer, noticeably improving the overall survival of cancer patients. In this sense, the inhibition of the programmed cell death receptor-1 (PD-1)/p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10814513f21ff0d8077258df6cef117c
https://doi.org/10.1039/c8nj05561k
https://doi.org/10.1039/c8nj05561k
Autor:
IL Arce, Mmr Hakel, J.B.A. Neto, G.M. Sales, V.F. Paiva, VC Queiroz, P Vicari, Jdp Paes, GA Géssica, V.C.F. Figueiredo, Ana Beatriz M. L. A. Tavares
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S514-S515 (2021)
Hematology, Transfusion and Cell Therapy
Hematology, Transfusion and Cell Therapy
Introdução: COVID-19 é o conjunto de sintomas causados pelo SARS-CoV-2, variando de quadros leves a formas graves. Pacientes com COVID-19 grave frequentemente apresentam marcadores laboratoriais anormais que refletem resposta inflamatória sistêm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f95f91f982a4002b3cf0b69481a24e6e
https://doi.org/10.1016/j.htct.2021.10.888
https://doi.org/10.1016/j.htct.2021.10.888
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Scientific Reports
Scientific Reports
Much of the recent excitement in the cancer immunotherapy approach has been generated by the recognition that immune checkpoint proteins, like the receptor PD-1, can be blocked by antibody-based drugs with profound effects. Promising clinical data ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::829c2ff727081e83ad36e3179500bdaa
http://link.springer.com/article/10.1038/s41598-018-20325-0
http://link.springer.com/article/10.1038/s41598-018-20325-0
Publikováno v:
Journal of Clinical Oncology. 36:e15089-e15089
e15089Background: Immunotherapy is nowadays an important active area of cancer research. In particular, the use of checkpoint inhibitors, such as the programmed cell death receptor PD-1, are being ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c90e0fb7632ea63919f50921f25c250f
https://doi.org/10.1200/jco.2018.36.15_suppl.e15089
https://doi.org/10.1200/jco.2018.36.15_suppl.e15089
Autor:
Eudenilson L. Albuquerque, Umberto L. Fulco, Ana Beatriz M. L. A. Tavares, J.X. Lima-Neto, L.R. da Silva
Publikováno v:
Journal of Clinical Oncology. 35:e14558-e14558
e14558 Background: Immunotherapy is a procedure to boost the patient's own immune system to fight diseases such as cancer. In some types of cancer, it has been found that the programmed cell death receptor PD-1 impedes the body's immune defenses from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb8b07f8c3ab215e406bf8efe8c06373
https://doi.org/10.1200/jco.2017.35.15_suppl.e14558
https://doi.org/10.1200/jco.2017.35.15_suppl.e14558